Segments of Business and Geographic Areas (Tables)

12 Months Ended

Dec. 30, 2012



	Sales to Customers
(Dollars in Millions)	2012		2011	2010
Consumer —
United States	$	5,046	5,151	5,519
International	9,401		9,732	9,071
Total	14,447		14,883	14,590
Pharmaceutical —
United States	12,421		12,386	12,519
International	12,930		11,982	9,877
Total	25,351		24,368	22,396
Medical Devices and Diagnostics —
United States	12,363		11,371	11,412
International	15,063		14,408	13,189
Total	27,426		25,779	24,601
Worldwide total	$	67,224	65,030	61,587



	Pre-Tax Profit				Identifiable Assets
(Dollars in Millions)	2012 ⁽³⁾		2011 ⁽⁴⁾	2010 ⁽⁵⁾	2012		2011	2010
Consumer	$	1,693	2,096	2,342	$	24,131	24,210	23,753
Pharmaceutical	6,075		6,406	7,086	23,219		23,747	19,961
Medical Devices and Diagnostics	7,187		5,263	8,272	42,926		23,609	23,277
Total	14,955		13,765	17,700	90,276		71,566	66,991
Less: Expense not allocated to segments ⁽¹⁾	1,180		1,404	753
General corporate ⁽²⁾					31,071		42,078	35,917
Worldwide total	$	13,775	12,361	16,947	$	121,347	113,644	102,908



	Additions to Property, Plant & Equipment				Depreciation and Amortization
(Dollars in Millions)	2012		2011	2010	2012		2011	2010
Consumer	$	468	670	526	$	575	631	532
Pharmaceutical	737		729	508	1,010		958	912
Medical Devices and Diagnostics	1,230		1,095	1,113	1,857		1,331	1,270
Segments total	2,435		2,494	2,147	3,442		2,920	2,714
General corporate	499		399	237	224		238	225
Worldwide total	$	2,934	2,893	2,384	$	3,666	3,158	2,939

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]



	Sales to Customers				Long-Lived Assets ⁽⁶⁾
(Dollars in Millions)	2012		2011	2010	2012		2011	2010
United States	$	29,830	28,908	29,450	$	35,115	23,529	23,315
Europe	16,945		17,129	15,510	25,261		19,056	16,791
Western Hemisphere excluding U.S.	7,207		6,418	5,550	3,636		3,517	3,653
Asia-Pacific, Africa	13,242		12,575	11,077	2,362		2,163	2,089
Segments total	67,224		65,030	61,587	66,374		48,265	45,848
General corporate					899		750	715
Other non long-lived assets					54,074		64,629	56,345
Worldwide total	$	67,224	65,030	61,587	$	121,347	113,644	102,908

See Note 1 for a description of the segments in which the Company operates.

Export sales are not significant. In 2012, 2011 and 2010, the Company did not have a customer that represented 10% of total revenues.


⁽¹⁾	Amounts not allocated to segments include interest (income) expense, noncontrolling interests and general corporate (income) expense. Includes expense of $0.2 billion and $0.5 billion of currency related expense related to the acquisition of Synthes, Inc. in 2012 and 2011, respectively.


⁽²⁾	General corporate includes cash and marketable securities.

⁽³⁾

Includes $1,218 million of net litigation expense, which includes product liability, comprised of $658 million and $560 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes $1,163 million of in-process research and development expense, comprised of $1,111 million and $52 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes $795 million of Synthes integration/transaction costs in the Medical Devices and Diagnostics segment. Includes $909 million of asset write-downs and other adjustments, comprised of $499 million, $264 million and $146 million in the Pharmaceutical, Consumer and Medical Devices and Diagnostics segments, respectively. The Medical Devices and Diagnostics segment also includes $110 million expense for the cost associated with the DePuy ASR™ Hip program.

⁽⁴⁾

Includes $3,310 million of net litigation expense, which includes product liability, comprised of $1,741 million and $1,569 million in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes $656 million of net restructuring expense, comprised of $676 million expense in the Medical Devices and Diagnostics segment and a gain of $20 million in the Pharmaceutical segment. The Medical Devices and Diagnostics segment also includes $521 million expense for the cost associated with the DePuy ASR™ Hip program.


⁽⁵⁾	Includes $397 million of net litigation gain, which includes product liability expense, comprised of $447 million expense in the Pharmaceutical segment and a gain of $844 million in the Medical Devices and Diagnostics segment. The Medical Devices and Diagnostics segment also includes $280 million expense for the cost associated with the DePuy ASR™ Hip program.


⁽⁶⁾	Long-lived assets include property, plant and equipment, net for 2012, 2011 and 2010 of $16,097, $14,739 and $14,553, respectively, and intangible assets and goodwill, net for 2012, 2011 and 2010 of $51,176, $34,276 and $32,010, respectively.

- Definition

Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.

+ References+ Details

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details